Teva meets profit expectations but misses on revenue
1 min readTeva Pharmaceutical Industries Ltd. (NYSE: TEVA TASE: TEVA) these days noted $3.7 billion income for the 1st quarter of 2022, down 8% from the corresponding quarter of 2021, and marginally down below the analysts’ consensus of $3.75 billion. Non-GAAP earnings for every share was $.55, assembly the analysts’ forecast.

Teva slash its 2022 income forecast from $15.6-16.2 billion to $15.4-16 billion and its Copaxone sales forecast from $850 million to $750 million.




Related Posts













In response, Teva’s share value is down 2.58% in premarket trading on the NYSE.

Teva president and CEO Kare Schultz claimed, We are pleased to keep on resolving opioid-relevant litigations with current settlements in Florida and Rhode Island such as the provision of lifesaving opioid solutions and restoration medications for these who need to have them.”

He ongoing: “Whilst easing of Covid-19 relevant constraints has led to good momentum in our European enterprise, we are viewing fluctuations of international exchange fees, and have consequently decreased our 2022 revenue outlook, even though reaffirming our earnings and income movement steerage.”

Released by Globes, Israel small business information – en.globes.co.il – on May 3, 2022.

© Copyright of Globes Publisher Itonut (1983) Ltd., 2022.